Trade Viking Therapeutics, Inc. - VKTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 65.07 |
| Open | 67.15 |
| 1-Year Change | 365.67% |
| Day's Range | 65.04 - 70.51 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 64.53 | 5.40 | 9.13% | 59.13 | 69.85 | 56.85 |
| Jul 24, 2024 | 50.25 | -0.47 | -0.93% | 50.72 | 52.08 | 50.24 |
| Jul 23, 2024 | 51.46 | 0.41 | 0.80% | 51.05 | 52.80 | 50.96 |
| Jul 22, 2024 | 51.70 | 0.94 | 1.85% | 50.76 | 51.84 | 48.73 |
| Jul 19, 2024 | 50.84 | 1.04 | 2.09% | 49.80 | 52.19 | 49.70 |
| Jul 18, 2024 | 50.03 | -0.93 | -1.82% | 50.96 | 51.60 | 48.46 |
| Jul 17, 2024 | 49.75 | -3.55 | -6.66% | 53.30 | 53.67 | 48.20 |
| Jul 16, 2024 | 56.90 | -2.90 | -4.85% | 59.80 | 60.13 | 56.70 |
| Jul 15, 2024 | 59.30 | 1.75 | 3.04% | 57.55 | 59.93 | 56.58 |
| Jul 12, 2024 | 57.08 | -1.67 | -2.84% | 58.75 | 59.66 | 57.08 |
| Jul 11, 2024 | 58.55 | 2.17 | 3.85% | 56.38 | 60.15 | 56.38 |
| Jul 10, 2024 | 57.95 | 3.80 | 7.02% | 54.15 | 58.58 | 54.15 |
| Jul 9, 2024 | 54.09 | 2.84 | 5.54% | 51.25 | 54.82 | 50.97 |
| Jul 8, 2024 | 50.96 | -0.68 | -1.32% | 51.64 | 53.10 | 50.12 |
| Jul 5, 2024 | 51.17 | 0.37 | 0.73% | 50.80 | 52.19 | 50.20 |
| Jul 3, 2024 | 50.42 | -1.39 | -2.68% | 51.81 | 52.50 | 49.80 |
| Jul 2, 2024 | 51.49 | -2.22 | -4.13% | 53.71 | 55.21 | 51.44 |
| Jul 1, 2024 | 55.24 | 2.14 | 4.03% | 53.10 | 58.18 | 52.45 |
| Jun 28, 2024 | 52.97 | 1.97 | 3.86% | 51.00 | 54.70 | 51.00 |
| Jun 27, 2024 | 50.69 | 0.24 | 0.48% | 50.45 | 51.37 | 47.85 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Viking Therapeutics, Inc. Company profile
About Viking Therapeutics Inc
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Viking Therapeutics Inc revenues was not reported. Net loss increased 39% to $55M. Higher net loss reflects Other Research and Development. increase of 42% to $43.4M (expense), Interest Income - Net decrease of 78% to $703K (income), Stock-based Compensation in R&D increase of 19% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.54 to -$0.71.
| Industry: | Bio Therapeutic Drugs |
9920 Pacific Heights Blvd, Suite 350
SAN DIEGO
CALIFORNIA 92121
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com